Zacks Investment Research
27 Oct 2026, 15:46 UTC · 1h ago
IQVIA Holdings Q3 Earnings Beat Estimates, Revenues Increase 8% Y/Y
Impact · against what's priced in
The earnings beat and guidance raise provide marginal upside for IQVIA as the current valuation already aggressively prices in high revenue growth and strong clinical bookings. The most material catalyst is the 15% increase in net new R&D bookings, which suggests a growth trajectory that may exceed the 10.6% CAGR the market currently demands.
- IQV+0.30
Not in the price yet
- The price assumes
implied revenue CAGR (reverse DCF): 10.6%
While the price already assumes 8.7% quarterly growth and record backlogs, the 15% year-over-year increase in net new R&D bookings ($3.2 billion) provides concrete evidence that revenue growth could accelerate beyond the 10.6% CAGR required to justify the current price.
What IQV's price assumes · Sep 24
